Mounjaro vs Zepbound: Which Is Right for You?
Mounjaro and Zepbound are both tirzepatide. The difference is the FDA label, the insurance pathway, and sometimes the price. Here's how to choose.
Updated May 6, 2026 · 5 min read
Mounjaro and Zepbound are the same drug — tirzepatide, made by Eli Lilly, in identical pens at identical strengths. The difference is the label on the box, the diagnosis it's billed under, and occasionally the cash price. That's it.
But that "that's it" hides a lot of practical chaos: a person with type 2 diabetes might be paying $25 a month for Mounjaro through their PBM, while their neighbor with a BMI of 32 is paying $1,060 a month for Zepbound out of pocket. Same molecule, same factory, same pen — different paperwork.
They are literally the same active drug
Both Mounjaro and Zepbound contain tirzepatide as a once-weekly subcutaneous injection.
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| Dose strengths | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| FDA approval | Type 2 diabetes (May 2022) | Chronic weight management (Nov 2023) |
| Pen format | Single-dose auto-injector | Single-dose auto-injector (and vial) |
| List price | ~$1,080/month | ~$1,060/month (vials cheaper) |
If you swapped the labels nothing about the medicine itself would change. The FDA reviewed and approved tirzepatide separately for each indication, which is why two brand names exist for one molecule.
The label is what insurance cares about
The label is the difference that costs people thousands of dollars.
- Mounjaro is billed under a type 2 diabetes diagnosis (ICD-10 codes in the E11 family). Most commercial plans and Medicare Part D cover it for diagnosed T2D, often with prior auth. Coverage for prediabetes or insulin resistance alone is usually denied.
- Zepbound is billed under obesity or overweight-with-comorbidity (BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition like sleep apnea, hypertension, or dyslipidemia). Many commercial plans explicitly exclude anti-obesity medications. Medicare did not cover anti-obesity drugs until very recently and the rules are still in flux.
A useful rule of thumb: if you have type 2 diabetes, your insurance is far more likely to cover Mounjaro. If you don't, you're either paying cash for Zepbound or fighting your plan's anti-obesity carve-out.
The savings cards are not interchangeable
Lilly runs separate savings programs for the two brands, and the rules differ enough to matter.
- Mounjaro Savings Card — historically as low as $25/month for commercially insured patients with covered prescriptions. Patients with no coverage or government insurance are not eligible.
- Zepbound Savings Card — discounts for commercially insured patients (often $25 with coverage, larger reductions without). Lilly also opened LillyDirect, a self-pay channel offering single-dose Zepbound vials at meaningfully lower prices than pen list price.
Both programs change quarterly. Always check the current terms on Lilly's site before assuming a number you read online still holds.
When asking your prescriber to switch makes sense
A switch isn't always necessary, but several scenarios make it worth raising:
- You're on Mounjaro for "off-label" weight loss and your insurer is auditing. Some PBMs are clawing back coverage when there's no T2D diagnosis on file. Switching to Zepbound (with a documented BMI) puts you on solid ground.
- You're paying cash for Zepbound pens and didn't know vials existed. LillyDirect vials can cut your monthly cost substantially.
- You have type 2 diabetes and you're on Zepbound. Your plan may cover Mounjaro for less under your diabetes benefit. Worth asking.
- You're stuck in a shortage of one but not the other. Historically rare for tirzepatide since FDA removed it from the shortage list in late 2024, but supply hiccups still happen at individual pharmacies.
The actual switch is uneventful — your prescriber writes for the new brand at the same dose. There's no titration reset, no washout, no re-acclimation. You're not changing drugs.
A quick note on compounded tirzepatide
Once the FDA declared the tirzepatide shortage resolved (October 2024, finalized early 2025), 503A and 503B compounders lost the legal basis to mass-produce tirzepatide copies. Some still operate in narrower personalization niches, but the broad "compounded tirz from a telehealth clinic" market shrank dramatically compared to the semaglutide compounding scene. If you're considering this route, our compounded tirzepatide cluster covers what's still legal, what's risky, and how to vet a supplier.
Which one is "right" for you — a short decision tree
- Type 2 diabetes, insurance covers Mounjaro → Mounjaro. Done.
- No T2D, BMI qualifies, insurance covers Zepbound → Zepbound. Done.
- No T2D, BMI qualifies, insurance excludes weight-loss drugs → Zepbound via LillyDirect vials, or appeal with comorbidity documentation, or look at tirzepatide vs semaglutide cost trade-offs.
- You have both T2D and obesity → Either is clinically reasonable; pick the one your plan covers better. Same drug.
- You're already stable on one brand → Don't switch unless there's a cost or coverage reason. Continuity of supply is its own value.
What it doesn't change
The dose ladder is identical (see tirzepatide dosing schedule). The side-effect profile is identical. The trial data — both SURMOUNT for weight management and SURPASS for T2D — applies to either label, because they were conducted on tirzepatide, not on a brand. If your provider switches you mid-course, you stay on the same milligrams and the same weekly cadence.